Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 1/20 | 0.59 |
| ▸ | DNM1 | Q05193 | 10/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PER2 | O15055 | 2/20 | 0.43 |
| ▸ | CRY1 | Q16526 | 2/20 | 0.43 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407490 | 0.94 | TSPO (0.70) | TSPODNM1MEN1MAPTKMT2A | |
| SCHEMBL28228400 | 0.92 | TSPO (0.62) | TSPODNM1MEN1MAPTKMT2A | |
| SCHEMBL407526 | 0.88 | TSPO (0.77) | TSPODNM1MEN1MAPTKMT2A | |
| SCHEMBL410621 | 0.88 | TSPO (0.77) | TSPODNM1MEN1MAPTKMT2A | |
| SCHEMBL406252 | 0.88 | TSPO (0.77) | TSPODNM1MEN1MAPTKMT2A | |
| SCHEMBL407411 | 0.88 | TSPO (0.58) | TSPODNM1MEN1MAPTKMT2A | |
| SCHEMBL12960306 | 0.87 | DNM1 (0.68) | TSPODNM1MEN1MAPTKMT2A | |
| SCHEMBL408442 | 0.85 | TSPO (0.55) | TSPODNM1MEN1MAPTKMT2A | |
| SCHEMBL411036 | 0.85 | TSPO (0.55) | TSPODNM1MEN1MAPTKMT2A | |
| SCHEMBL16709579 | 0.85 | DNM1 (0.56) | TSPODNM1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172827-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-08 | — | — | US | claimed |
| US-20180318255-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2018-11-08 | — | — | US | claimed |
| EP-2385829-B1 | PRO-NEUROGENIC COMPOUNDS | UNIV TEXAS (US) | 2018-08-01 | — | — | EP | claimed |
| EP-2590647-B1 | PRO-NEUROGENIC COMPOUNDS | UNIV TEXAS (US) | 2017-11-08 | — | — | EP | claimed |
| US-20170157092-A1 | Anti-depression Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-06-08 | — | — | US | claimed |
| US-9616048-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-04-11 | — | — | US | claimed |
| US-20160362372-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2016-12-15 | — | — | US | claimed |
| US-20160206594-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-07-21 | — | — | US | claimed |
| US-20160206596-A1 | Anti-depression Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-07-21 | — | — | US | claimed |
| US-9162980-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-10-20 | — | — | US | claimed |
| EP-2590647-A2 | PRO-NEUROGENIC COMPOUNDS | Board of Regents of the University of Texas System (US) | 2013-05-15 | — | — | EP | claimed |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2013-02-14 | — | — | US | claimed |
| US-8362277-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-01-29 | — | — | US | claimed |
| US-20120022096-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-26 | — | — | US | claimed |
| WO-2012006419-A2 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-12 | — | — | WO | claimed |
| EP-2385829-A1 | PRO-NEUROGENIC COMPOUNDS | Board of Regents of the University of Texas System (US) | 2011-11-16 | — | — | EP | claimed |
| US-8039041-B2 | Electroluminescent devices with electrode protection | CAMBRIDGE DISPLAY TECHNOLOGY, LTD. (GB) | 2011-10-18 | — | — | US | claimed |
| US-20110015217-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-01-20 | — | — | US | claimed |
| US-20110003836-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-01-06 | — | — | US | claimed |
| WO-2010081115-A1 | PRO-NEUROGENIC COMPOUNDS | UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) | 2010-07-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022096-A1 | PRO-NEUROGENIC COMPOUNDS | BDNF, GAP43, DCX | TSPO 2470/4885DNM1 897/4885MEN1 3423/4885 |
| US-20160206594-A1 | Pro-Neurogenic Compounds | DCX, GAP43, BDNF | TSPO 826/4885DNM1 510/4885MEN1 3192/4885 |
| US-10172827-B2 | Pro-neurogenic compounds | DCX, GAP43, BDNF | TSPO 826/4885DNM1 510/4885MEN1 3192/4885 |
| US-20180318255-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | TSPO 2470/4885DNM1 897/4885MEN1 3423/4885 |
| US-20110015217-A1 | Pro-Neurogenic Compounds | DCX, GAP43, BDNF | TSPO 826/4885DNM1 510/4885MEN1 3192/4885 |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | TSPO 2470/4885DNM1 897/4885MEN1 3423/4885 |
| US-20110003836-A1 | Pro-Neurogenic Compounds | DCX, GAP43, BDNF | TSPO 794/4885DNM1 538/4885MEN1 3234/4885 |
| US-20160362372-A1 | PRO-NEUROGENIC COMPOUNDS | DCX, GAP43, BDNF | TSPO 826/4885DNM1 510/4885MEN1 3192/4885 |
| US-20160206596-A1 | Anti-depression Compounds | BDNF, DCX, GAP43 | TSPO 2600/4885DNM1 638/4885MEN1 4295/4885 |
| US-20170157092-A1 | Anti-depression Compounds | BDNF, DCX, GAP43 | TSPO 2600/4885DNM1 638/4885MEN1 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.